British Regulator Launches "Learning Module" on Oral Anticoagulants Including Xarelto, Notes Rottenstein Law Group LLP

Lawrence, New York   August 13, 2014   Business News
(PRLEAP.COM) August 13, 2014 - The Rottenstein Law Group, a national personal injury law firm that represents persons who believe they were injured by anticoagulants such as Pradaxa and Xarelto, has learned that the Medicines and Healthcare products Regulatory Agency (MHRA) has launched an online learning module for healthcare professionals on reducing the side effects of oral anticoagulants, such as Xarelto (www.xareltoinjuryfirm.com) and Pradaxa.

According to a press release dated August 5 and published by the MHRA: "Anticoagulants are vital medicines for treating and preventing blood clots. However, if the patient is not managed correctly their side effects can lead to a small number of people needing hospital treatment. With the right precautions, many of these side effects can be prevented. Designed for doctors, nurses and pharmacists, the interactive [program] takes the learner through key points about these medicines, how to manage the risks and, importantly, how to make sure patients get the most benefit from these medicines.*

"It is gratifying to learn that the United Kingdom is taking the alleged dangers of Xarelto and related drugs seriously," said Rochelle Rottenstein, principal of the Rottenstein Law Group. "We have read allegations that Xarelto's manufacturers should have recalled the product when they learned about the substantial dangers. Our goal is to make it as easy as possible for anyone possibly harmed by Xarelto to learn about those dangers and about legal options for demanding compensation for injuries suffered."

In 2013, the U.S. FDA received several hundred adverse event reports submitted by individuals who claimed to have a serious adverse side effect while taking Xarelto (rivaroxaban), as compared to a lower number for Pradaxa (dabigatran).** Data show that the number of persons being prescribed these blood thinning drugs is estimated at about 4 million for the year, with Xarelto prescriptions outnumbering Pradaxa prescriptions by two-to-one.** Anticoagulants (or "blood thinners") are considered high-risk prescription drugs because they can cause excessive internal bleeding and other injuries in some patients.

Anyone needing more information about the dangers of Xarelto should visit the firm's Xarelto site (www.xareltoinjuryfirm.com), where everything is explained in clear, concise language. Representatives of the firm are available to answer any questions, and there is a confidential, no-cost claim evaluation form that can be filled out in order to determine if there are grounds to file a Xarelto lawsuit.

* http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON444302
**http://www.ismp.org/quarterwatch/pdfs/2013Q1.pdf

ABOUT THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
100 Merrick Road
Suite 226W
Rockville Centre, NY 11570
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com
Contact Information
Rochelle Rottenstein
Rottenstein Law Group LLP
2129339500
Contact Us